Selvita

Krakow, Poland Founded: 2007 • Age: 19 yrs Listed
Selvita is recognized as a drug discovery and development provider.

About Selvita

Selvita is a publicly listed company based in Krakow (Poland) founded in 2007 by Boguslaw Sieczkowski. Selvita is recognized as a drug discovery and development provider. It operates on a Professional Services and Managed Services model. The company has 969 employees. Selvita has completed 2 acquisitions, including Fidelta and PozLab. Its chief executive, as recorded, is Boguslaw Sieczkowski. Its website selvita.com draws about 22 thousand monthly visits. Selvita offers products and services including Drug Discovery Services and Drug Development Services. Its focus areas include Pharmaceuticals and Drug Discovery and Development. Its legal entity is Selvita S.A.

Company details

Selvita is established as an integrated service provider in drug discovery and development, offering comprehensive solutions to support customers and projects. Services are provided across various modalities including small molecules, antibodies, and biologics. Expertise is maintained in medicinal chemistry, pharmacology, and regulatory compliance under GMP and GLP standards. Operations are focused on bridging early discovery to clinical development, covering multiple therapeutic areas with a flexible engagement model for standalone or integrated programs.

  • Headquarters Krakow, Poland
  • Employees 969
  • Founders Boguslaw Sieczkowski
  • Stage Public
  • Sectors
    Healthcare
  • Email
    ••••••••
  • Phone
    •••• ••••
  • Website selvita.com
  • Social LinkedIn X Facebook YouTube
  • Legal Name Selvita Sa
Operational Areas
Key Metrics
  • Annual Revenue
    $101.46 M (USD)
    6.57
    as on Dec 31, 2025
  • Net Profit
    $226.31 K (USD)
    as on Dec 31, 2025
  • EBITDA
    $17.19 M (USD)
    26.4
    as on Dec 31, 2025
  • Latest Funding Round
    $5.5M (USD), Post-IPO

    May 2011

  • Employee Count
    969
  • Investments & Acquisitions
    Fidelta

    & 1 more

Products & Services of Selvita

Selvita offers a comprehensive portfolio of products and services, including Drug Discovery Services and Drug Development Services.

Drug Discovery Services
Pharmaceutical Services

Comprehensive drug discovery from target to preclinical candidate.

Drug Development Services
Pharmaceutical Services

End-to-end drug development with regulatory and analytical support.

Apps and channels of Selvita

its YouTube channel Selvita has 214 subscribers and 22 videos.

Selvita
YouTube 214 subscribers 22 videos Science & Technology
Open channel

Videos from Selvita

The most watched videos on Selvita's YouTube channel, Selvita (214 subscribers). Click a video to play it here.

We are Selvita. Together we transform science into discoveries.
1.7K views
Passion for science drives discoveries
1.2K views
The New Selvita
684 views
Official Opening of Selvita Research Centre
432 views

More on Selvita.

Funding Insights of Selvita

  • Total Rounds 1
  • Last Round Post-IPO — $5.5M
  • First Round $5.5M

    (May 2011)

All 1 funding rounds of Selvita with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
May 2011$5.5MPost-IPO––
–

People of Selvita

1 people are tracked at Selvita (1 in leadership); the tracked headcount is 969.

NameRoleGroup
Boguslaw Sieczkowski
Co-Founder & CEOLeadership
Premium access

Complete people profiles for Selvita

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Selvita

Selvita is a publicly listed company on the GPW with ticker symbol SLV in Poland, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date16 Mar 2021
  • Listed onWSE: SLV
  • Listed entitySelvita SA
  • Exchange sectorHealth technology
  • ISINPLSLVCR00029
  • Share price20.75 PLN (+0.24% on the day) · 2026-10-14
  • Market capitalisation379,958,336.00 PLN
  • EPS (diluted, trailing year)-0.11 PLN
  • Volume (last session)6,793

Financials of Selvita

Exchange-reported annual figures
YearRevenueNet incomeEBITDA
2025364.5M PLN813,000 PLN61.8M PLN
2024342.0M PLN-6.1M PLN48.9M PLN
2023347.0M PLN69.9M PLN57.6M PLN
2022360.7M PLN30.3M PLN71.5M PLN
2021310.9M PLN14.9M PLN47.6M PLN
Premium access

Detailed financial statements for Selvita

Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.

  • Statement rows
  • Financial ratios
  • Five-year trends
  • Downloads

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Selvita

Selvita has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Fidelta and PozLab.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
Formulation and process development services for pharmaceuticals are provided.
pozlab.plPoznan, Poland2010Mar 2024$6.29M
Integrated preclinical drug discovery services are provided by Fidelta.
fidelta.euZagreb, Croatia1952Nov 2020$36.99M
Premium access

Complete acquisition details for Selvita

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of Selvita

5 dated milestones of Selvita across 17 years, from founding to its latest funding, stage changes and deals.

  1. Founded Selvita is founded.
  2. Funding First funding round of $5.5M.
  3. Acquisition Acquires Fidelta.
  4. IPO Lists on the stock exchange (IPO).
  5. Acquisition Acquires PozLab.

Web traffic of Selvita

The website of Selvita (selvita.com) receives about 22.5K visits a month.

  • Monthly visits
    22.5K

    ▲ 103.5% vs previous month

Similar websites

Websites whose visitors overlap most with Selvita. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
biocentrum.com.pl
100%
View details
criver.com
90%
224.6K#186,811View details
apeiron.edu.pl
apeiron.edu.pl
57%
#1,586,352–
oru.se
54%
1.3M#44,777View details
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Selvita

Premium access

Complete news archive for Selvita

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Selvita

Selvita was founded in 2007 and raised its 1st funding round 4 years after it was founded.

Selvita is headquartered in Krakow, Poland. It is registered at Krakow, Lesser Poland Voivodeship, Poland.

Boguslaw Sieczkowski is the CEO of Selvita, as recorded in our data. They have also founded this company.

Selvita has 969 employees.

Annual revenue of Selvita is $101.46M as on Dec 31, 2025.

Selvita is established as an integrated service provider in drug discovery and development, offering comprehensive solutions to support customers and projects. Services are provided across various modalities including small molecules, antibodies, and biologics. Expertise is maintained in medicinal chemistry, pharmacology, and regulatory compliance under GMP and GLP standards. Operations are focused on bridging early discovery to clinical development, covering multiple therapeutic areas with a flexible engagement model for standalone or integrated programs.

Selvita offers Drug Discovery Services and Drug Development Services.

Yes, Selvita is publicly traded on GPW under the ticker symbol SLV.

Selvita has made 2 acquisitions, including Fidelta, and PozLab.

Selvita operates through Selvita S.A..

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available